In-vivo delivery of therapeutic proteins by genetically-modified cells: Comparison of organoids and human serum albumin alginate-coated beads

Biomedicine and Pharmacotherapy

Volumn 53, Issue 10, 1999, Pages 471-483

  Shinya, E ^a   Dervillez, X ^b   Edwards Levy F ^c   Duret, V ^b   Brisson, E ^a   Ylisastigui, L ^a   Levy M C ^c   Cohen, J H M ^b   Klatzmann, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Gene therapy; HIV; Multivalent

Indexed keywords

BINDING PROTEIN; CD4 ANTIGEN DERIVATIVE; HYBRID PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TRANSPLANTATION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN TRANSPORT;

EID: 0033397389     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88106-8     Document Type: Article

References (47)

1. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: A novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87 : 5095-103.
2. Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts-an alternate approach to somatic gene therapy. Hum Gene Ther 1995; 6 : 165-75.
3. Moullier P, Marechal V, Danos O, Heard JM. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts. Transplantation 1993; 56 : 427-32.
4. Moullier P, Bohl D, Heard JM, Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts [comments]. Nat Genet 1993; 4 : 154-9.
5. Moullier P, Bohl D, Cardoso J, Heard JM, Danos O. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nat Med 1995; 1 : 353-7.
6. Bohl D, Salvetti A, Moullier P, Heard JM. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92 : 1512-7.
7. Leroy-Viard K, Rouyer-Fessard P, Beuzard Y. Improvement of mouse beta-thalassemia by recombinant human erythropoietin. Blood 1991; 78 : 1596-602.
8. Villeval J, Rouyer-Fessard P, Blumenfeld N, Henri A. Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves murine beta thalassemia. Blood 1994; 84 : 928-33.
9. Olivieri N, Freedman M, Perrine S, Dover G, Sheridan B. Trial of recombinant erythropoietin: Three patients with thalassemia intermedia. Blood 1992; 80 : 3258-64.
10. Rachmilewitz E, Goldfarb A, Dover G. Administration of erythropoietin to patients with beta-thalassemia intermedia: A preliminary trial. Blood 1988; 80 : 1145-53.
11. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N. Recombinant erythropoictin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol 1997; 98 : 199-203.
12. Chang PL, Van Raamsdonk JM, Hortelano G, Barsoum SC, MacDonald NC, Stockley TL. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotechnol 1999; 17 : 78-83.
13. Tai IT, Sun AM. Microencapsulation of recombinant cells: A new delivery system for gene therapy. Faseb J 1993; 7 : 1061-9.
14. Lanza RP, Chick WL. Immunoisolation: At a turning point. Immunol Today 1997; 18 : 135-9.
15. Valere T, Bohl D, Klatzmann D, Danos O, Sonigo P, Heard JM. Continuous secretion of human soluble CD4 in mice transplanted with genetically modified cells. Gene Ther 1995; 2 : 197-202.
16. Kahn JO, Allan JD, Hodges TL, Kaplan LD, Arri CJ, Fitch HF, et al. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study [comments]. Ann Intern Med 1990; 112 : 254-61.
17. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337 : 525-31.
18. Trauneker A, Schneider J, Kiefer H, Karjalainen K. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989; 339 : 68-75.
19. Idziorek T, Klatzmann D. Construction of CD4-based chimeric molecules by chemical cross-linking. AIDS Res Hum Retro-viruses 1991; 7 : 529-36.
20. Yen P, Landais D, Lemaitre M, Maury I, Crenne JY, Becquart J, et al. Design of yeast-secreted albumin derivatives for human therapy: Biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 1992; 89 : 1904-8.
21. Berkower I, Mostowski H, Bull TE, Murphy D. CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1. J Inf Dis 1996; 173 : 863-9.
22. Libyh MT, Goossens D, Oudin S, Gupta N, Dervillez X, Juszczak G, et al. A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein. Blood 1997; 90 : 3978-83.
23. Levy MC, Edwards-Levy F. Coating alginate beads with cross-linked biopolymers: A novel method based on a transacylation reaction. J Microencapsul 1996; 13 : 169-83.
24. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milman CI. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration. AIDS 1994; 8: 169-81.
25. Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331 : 82-4.
26. Charneau P, Alizon M, Clavel F. A second origin of DNA plusstrand synthesis is required for optimal human immunodeficiency virus replication. J Virol 1992; 66 : 2814-20.
27. Taylor GM, Morton JE, Morton H, Dodge AB, Ridway JC, Jones PM, et al. Expression of the human CD4 by two human-mouse interlineage hybrids. J Immunogenet 1988; 15 : 197-208.
28. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990; 112 : 247-53.
29. Clapham PR, Weber JN, Whitby D, McIntosh K, Dalgleish AG, Maddon PJ, et al. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989; 337 : 368-70.
30. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, et al. Biological properties of a CD4 immunoadhesion. Nature 1990; 344 : 667-70.
31. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988; 331 : 76-8.
32. Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331 : 78-81.
33. Traunecker A, Luke W, Karjalainen K. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 1988; 331:84-6.
34. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990; 87 : 6574-8.
35. Moore JP, McKeating JA, Norton WA, Sattentau A. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp 120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J Virol 1991; 65 : 1133-40.
36. Joly A, Desjardins JF, Fremond B, Desille M, Campion JP, Malledant Y, et al. Survival, proliferation, and functions of porcine hepatocytes encapsulated in coated alginate beads: A step toward a reliable bioartificial liver. Transplantation 1997; 63 : 795-803.
37. Brauker J, Frost GH, Dwarki V, Nijjar T, Chin R, Carr-Brendel V, et al. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum Gene Ther 1998; 9 : 879-88.
38. Serguera C, Bohl D, Rolland E, Prevost P, Heard JM. Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells. Hum Gene Ther 1999; 10 : 375-83.
39. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268 : 1766-9.
40. Magari SR, Rivera VM, Iuliucci JD, Gilman M, Cerasoli F Jr. Pharmacologic control of a humanized gene therapy system implanted into nude mice. J Clin Invest 1997; 100 : 2865-72.
41. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70 : 8098-108.
42. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93 : 14082-7.
43. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94 : 5804-9.
44. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8 : 1891-900.
45. Clark KR, Sferra TJ, Johnson PR. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8 : 659-69.
46. Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci USA 1997; 94 : 13921-6.
47. Rendahl KG, Leff SE, Otten GR, Spratt SK, Bohl D, Van Roey M, et al. Regulation of gene expression in vivo following transduction by two separate rAAv vectors. Nat Biotechnol 1998; 16:757-61.